Sigrid Therapeutics

Sigrid Therapeutics is a clinical-stage health technology and biotechnology company based in Stockholm, Sweden. Founded in 2014, the company focuses on preventing and managing chronic metabolic diseases such as prediabetes, type 2 diabetes, and obesity. Sigrid's innovative approach utilizes its proprietary SiPore® Technology, which employs micron-sized mesoporous silica particles to reduce calorie uptake and lower blood sugar spikes without systemic absorption.

The company offers key products like SiPore15®, a silica-based powder that supports long-term blood sugar control and weight management, and SiPore21® (Carb Fence), an orally consumed gel that provides a non-pharmaceutical alternative for managing blood sugar levels. Sigrid has completed multiple clinical trials, including the SHINE study, demonstrating the safety and efficacy of its products. With over 10 patents and collaborations with prestigious institutions, Sigrid Therapeutics is dedicated to advancing metabolic health solutions for individuals at risk of or living with metabolic conditions.